These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12434469)

  • 1. Multiple myeloma and its treatment.
    Felder B
    Clin J Oncol Nurs; 2002; 6(6):359-62. PubMed ID: 12434469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of multiple myeloma].
    Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
    G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: epidemiology and therapeutic options.
    Tuscano JM
    Manag Care; 2008 Jul; 17(7 Suppl 6):9-15. PubMed ID: 19093334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches in the treatment of multiple myeloma.
    Abedi M; Elfenbein GJ
    Med Health R I; 2003 Aug; 86(8):231-5. PubMed ID: 14582216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update: health economics of managing multiple myeloma.
    Moeremans K; Annemans L
    Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
    Patriarca F; Sperotto A; Filì C; Zaja F; Prosdocimo S; Fanin R
    Haematologica; 2002 Jul; 87(7):779-81. PubMed ID: 12091134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
    Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
    Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
    Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R
    Haematologica; 2003 May; 88(5):597-9. PubMed ID: 12745281
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCCN: Multiple myeloma.
    Traynor AE; Noga SJ;
    Cancer Control; 2001; 8(6 Suppl 2):78-87. PubMed ID: 11760563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nosocomial respiratory syncytial virus infections in three cases in a bone marrow transplantation unit].
    Kalayoglu Beşişik S; Sen F; Midilli K; Yilmaz G; Ozsüt H; Calangu S; Sargin D
    Mikrobiyol Bul; 2008 Apr; 42(2):359-64. PubMed ID: 18697436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.